The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
14hon MSN
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
Civic Science on MSN10h
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus MoreThis is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback